Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma-Reference-Cited by-同舟云学术

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

Published:2021-07-22 Issue:4 Volume:194 Page:690-700
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Oluwole Olalekan O.¹,Bouabdallah Krimo²,Muñoz Javier³,De Guibert Sophie⁴,Vose Julie M.⁵,Bartlett Nancy L.⁶,Lin Yi⁷,Deol Abhinav⁸,McSweeney Peter A.⁹,Goy Andre H.¹⁰,Kersten Marie José¹¹,Jacobson Caron A.¹²,Farooq Umar¹³^ORCID,Minnema Monique C.¹⁴,Thieblemont Catherine¹⁵,Timmerman John M.¹⁶,Stiff Patrick¹⁷,Avivi Irit¹⁸,Tzachanis Dimitrios¹⁹,Kim Jenny J.²⁰,Bashir Zahid²⁰,McLeroy Jeff²⁰,Zheng Yan²⁰,Rossi John M.²⁰,Johnson Lisa²⁰,Goyal Lovely²⁰,Meerten Tom²¹

Affiliation:

1. Vanderbilt‐Ingraham Cancer Center Nashville TN USA

2. Service d'Hématologie et Thérapie Cellulaire CHU Bordeaux Bordeaux France

3. Banner MD Anderson Cancer Center Gilbert AZ USA

4. Hôpital de Pontchaillou Rennes France

5. University of Nebraska Medical Center Omaha NE USA

6. Siteman Cancer Center Washington University School of Medicine St. Louis MO USA

7. Mayo Clinic Rochester MN USA

8. Karmanos Cancer Center Wayne State University Detroit MI USA

9. Colorado Blood Cancer Institute Denver CO USA

10. John Theurer Cancer Center Hackensack University Medical Center Hackensack NJ USA

11. Amsterdam UMC University of Amsterdam Amsterdam Netherlands on behalf of HOVON/LLPC

12. Dana‐Farber Cancer Institute Boston MA USA

13. University of Iowa Iowa City IA USA

14. University Medical Center Utrecht Utrecht Netherlands on behalf of HOVON/LLPC

15. Université de Paris AP‐HP, Hôpital Saint‐Louis Hemato‐oncology, DMU HI; Research Unit NF‐kappaB Différenciation et Cancer Paris France

16. UCLA David Geffen School of Medicine Los Angeles CA USA

17. Loyola University Chicago Stritch School of Medicine Maywood IL USA

18. Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

19. Moores Cancer Center, UCSD La Jolla CA USA

20. Kite, a Gilead Company Santa Monica CA USA

21. University Medical Center Groningen Groningen Netherlands on behalf of HOVON/PPLC

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17527

Reference32 articles.

1. YESCARTA®(axicabtagene ciloleucel) [summary of product characteristics].Amsterdam the Netherlands:Kite Pharma EU B.V.;2018.

2. YESCARTA®(axicabtagene ciloleucel) Prescribing information. KitePharma Inc;2021.

3. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

4. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

5. In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy;Transplantation and Cellular Therapy;2024-09

2. CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey;Frontiers in Medicine;2024-08-28

3. CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations;Blood Advances;2024-08-16

4. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention;Blood Advances;2024-08-15

5. Policy and perspective on outpatient programs for autologous hematopoietic cell transplantation and immune-effector cell therapy administration;Frontiers in Immunology;2024-08-06